Bicara Therapeutics Inc.
BCAX
$24.28
$0.652.75%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 42.75M | 35.80M | 30.51M | 29.13M | 26.19M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 201.99M | 174.06M | 155.60M | 141.12M | 121.07M |
| Operating Income | -201.99M | -174.06M | -155.60M | -141.12M | -121.07M |
| Income Before Tax | -185.16M | -157.12M | -137.73M | -121.17M | -102.36M |
| Income Tax Expenses | 206.00K | 197.00K | 217.00K | 350.00K | 310.00K |
| Earnings from Continuing Operations | -185.36 | -157.32 | -137.95 | -121.52 | -102.67 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -185.36M | -157.32M | -137.95M | -121.52M | -102.67M |
| EBIT | -201.99M | -174.06M | -155.60M | -141.12M | -121.07M |
| EBITDA | -201.84M | -173.93M | -155.50M | -141.04M | -121.00M |
| EPS Basic | -3.09 | -2.77 | -2.52 | -2.23 | -3.17 |
| Normalized Basic EPS | -1.93 | -1.73 | -1.57 | -1.39 | -1.98 |
| EPS Diluted | -3.09 | -2.77 | -2.52 | -2.23 | -3.17 |
| Normalized Diluted EPS | -1.93 | -1.73 | -1.57 | -1.39 | -1.98 |
| Average Basic Shares Outstanding | 238.35M | 224.96M | 218.70M | 217.98M | 174.32M |
| Average Diluted Shares Outstanding | 238.35M | 224.96M | 218.70M | 217.98M | 174.32M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |